A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression

The introduction of highly selective ABL-tyrosine kinase inhibitors (TKIs) has revolutionized therapy for chronic myeloid leukemia (CML). However, TKIs are only efficacious in the chronic phase of the disease and effective therapies for TKI-refractory CML, or after progression to blast crisis (BC),...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Exp Med
Main Authors: Giotopoulos, George, van der Weyden, Louise, Osaki, Hikari, Rust, Alistair G., Gallipoli, Paolo, Meduri, Eshwar, Horton, Sarah J., Chan, Wai-In, Foster, Donna, Prinjha, Rab K., Pimanda, John E., Tenen, Daniel G., Vassiliou, George S., Koschmieder, Steffen, Adams, David J., Huntly, Brian J.P.
Formato: Artigo
Idioma:Inglês
Publicado em: The Rockefeller University Press 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4577832/
https://ncbi.nlm.nih.gov/pubmed/26304963
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1084/jem.20141661
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados